Freenome wins $300m funding for multiomics blood testing platform
The funding will help the company to accelerate the commercialisation of its blood test for colorectal cancer (CRC)…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Dec 21
The funding will help the company to accelerate the commercialisation of its blood test for colorectal cancer (CRC)…
08 Dec 21
HealthPulse@home provides a faster, less expensive, hassle-free option for laboratories looking to offer COVID-19 specimen collection kits in…
08 Dec 21
Flagship has unveiled the new company with $50m committed capital, after three years of research and development
08 Dec 21
StrandDx-ASD is developed based on Linus Biotechnology's proprietary exposome and biological response sequencing platform
07 Dec 21
According to the company's analysis, its Covid-19 test portfolio has detection coverage for all variants of interest and…
07 Dec 21
Cernostics' TissueCypher platform leverages an approach that consolidates important elements of AI to deliver the spatialomics revolution to…
07 Dec 21
Embecta will be an independent, publicly-traded company, upon the completion of the transaction
07 Dec 21
The Galleri multi-cancer early detection test can detect more than 50 types of cancers
06 Dec 21
By delivering results within one hour, the test provides a rapid and cost-effective solution for identifying the Omicron…
06 Dec 21
The tests deploy quantitative polymerase chain reaction (qPCR) technology to improve variant detection and viral research